Melinta Therapeutics Reports First Patient Treated in Phase 2 Study of Topical Radezolid for Treatment of Acne
November 13 2017 - 7:00AM
Melinta Therapeutics, Inc. (NASDAQ:MLNT) a commercial-stage company
developing and commercializing novel antibiotics to treat serious
bacterial infections, announced today that the company’s partner
has initiated a Phase 2 clinical study of topical radezolid for the
treatment of mild-to-moderate acne vulgaris.
The Phase 2 study will enroll approximately 48 individuals with
moderate-to-severe facial acne vulgaris who will be randomized in a
double-blind fashion to receive a topical formulation of radezolid
or placebo that they will apply twice daily for 12-weeks. Primary
endpoints will include the Investigator's Global Assessment (score
of "clear" or “almost clear”) and the absolute change from baseline
of acne lesion count(s) in each treatment group. The study is
expected to complete enrollment in the second half of 2018.
“Radezolid for acne vulgaris has progressed extremely well
though preclinical and clinical development to date” commented Sue
Cammarata, Melinta’s chief medical officer. “With resistance to
currently available topical antibiotics rising, we believe that
radezolid could be an important treatment option for physicians and
patients affected by acne vulgaris and are very pleased it is
moving into Phase 2 development.”
In January 2015, Melinta structured an agreement with a third
party for topical indications of radezolid. The deal
structure provides Melinta with a potential long-term financial
return and affords Melinta the opportunity to participate in
radezolid’s future development and commercialization.
About Radezolid Radezolid is a
second-generation oxazolidinone antibiotic discovered by Melinta
scientists using proprietary, structure-based design, to achieve
higher ribosomal binding affinity, minimal off-target activity, and
a broader spectrum of antimicrobial activity than is currently
available in the class. For more information, please visit the
company website.
About Melinta Therapeutics Melinta
Therapeutics, Inc. is dedicated to saving lives threatened by the
global public health crisis of bacterial infections, through the
development and commercialization of novel antibiotics that provide
new and better therapeutic solutions. Melinta’s lead product is
Baxdela, an antibiotic approved by the US FDA for use in the
treatment of acute bacterial skin and skin structure infections
(ABSSSI). Melinta also has an extensive pipeline of preclinical and
clinical stage products representing many important classes of
antibiotics, each targeted at a different segment of the
anti-infective market. Together, this pipeline provides
Melinta with the unique ability to provide doctors and patients
with a range of solutions that can meet the tremendous need for
novel antibiotics treating serious infections. Visit
www.melinta.com for more information.
Cautionary Note Regarding Forward-Looking
Statements
Certain statements in this communication constitute
“forward-looking statements” within the meaning of Section 27A of
the Securities Act and Section 21E of the Securities Exchange Act
and are usually identified by the use of words such as
“anticipates,” “believes,” “estimates,” “expects,” “intends,”
“may,” “plans,” “projects,” “seeks,” “should,” “will,” and
variations of such words or similar expressions. We intend these
forward-looking statements to be covered by the safe harbor
provisions for forward-looking statements contained in Section 27A
of the Securities Act and Section 21E of the Securities Exchange
Act and are making this statement for purposes of complying with
those safe harbor provisions. These forward-looking statements
reflect our current views about our plans, intentions,
expectations, strategies and prospects, which are based on the
information currently available to us and on assumptions we have
made. Although we believe that our plans, intentions, expectations,
strategies and prospects as reflected in or suggested by those
forward-looking statements are reasonable, we can give no assurance
that the plans, intentions, expectations or strategies will be
attained or achieved. Furthermore, actual results may differ
materially from those described in the forward-looking statements
and will be affected by a variety of risks and factors that are
beyond our control.
Risks and uncertainties for the company include, but are not
limited to: liquidity and trading market for shares following
the consummation of the merger; risks related to the costs, timing
and regulatory review of the company’s studies and clinical trials,
including its ability to address the issues identified by the FDA
in the complete response letter relating to the company’s new drug
applications for solithromycin for community acquired bacterial
pneumonia; uncertainties in obtaining successful clinical results
for product candidates and unexpected costs that may result
therefrom; inability or the delay in obtaining required regulatory
approvals for product candidates, which may result in unexpected
cost expenditures; failure to realize any value of certain product
candidates developed and being developed, in light of inherent
risks and difficulties involved in successfully bringing product
candidates to market; inability to develop new product candidates
and support existing products; inability to commercialize and
launch any product candidate that receives regulatory approval,
including Baxdela; the company’s anticipated capital expenditures,
its estimates regarding its capital requirements and its need for
future capital; uncertainties of cash flows and inability to meet
working capital needs; cost reductions that may not result in
anticipated level of cost savings or cost reductions; the approval
by the FDA and EMA and any other similar foreign regulatory
authorities of other competing or superior products brought to
market; risks resulting from unforeseen side effects; risk that the
market for the company’s products may not be as large as expected;
inability to obtain, maintain and enforce patents and other
intellectual property rights or the unexpected costs associated
with such enforcement or litigation; inability to obtain and
maintain commercial manufacturing arrangements with third party
manufacturers or establish commercial scale manufacturing
capabilities; loss of or diminished demand from one or more key
customers or distributors; unexpected cost increases and pricing
pressures; the possibility of economic recession and its negative
impact on customers, vendors or suppliers; and risks associated
with the possible failure to realize certain benefits of the
merger, including future financial, tax, accounting treatment, and
operating results. Many of these factors that will determine
actual results are beyond the company’s ability to control or
predict.
Other risks and uncertainties are more fully described in the
company’s Annual Report on Form 10-K for the year ended December
31, 2016, as amended by Form 10-K/A filed with the SEC on April 13,
2017, and in other filings that the company has made and that the
company will make with the SEC, including the proxy statement
described below under “Important Information and Where to Find It.”
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date hereof. The statements made in this press release
or presentation speak only as of the date stated herein, and
subsequent events and developments may cause our expectations and
beliefs to change. While we may elect to update these
forward-looking statements publicly at some point in the future, we
specifically disclaim any obligation to do so, whether as a result
of new information, future events or otherwise, except as required
by law. These forward-looking statements should not be relied upon
as representing our views as of any date after the date stated
herein.
Important Information and Where to Find It
Stockholders may obtain, free of charge, copies of the
definitive proxy statement and any other documents filed by the
company with the SEC at the SEC’s website (http://www.sec.gov), at
the company’s website (http://ir.melinta.com/), or by writing to
the Secretary, Melinta Therapeutics, Inc., at ir@melinta.com.
For More Information:
Media Inquiries:Lyn Baranowski(203) 848-3346news@melinta.com
Investor Inquiries:John Bluth(984)
209-4534jbluth@melinta.com
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Melinta Therapeutics (NASDAQ:MLNT)
Historical Stock Chart
From Jul 2023 to Jul 2024